Cargando…
Arthus Reaction as an Adverse Event Following Tdap Vaccination
Repeat administration of tetanus toxoid-containing vaccines has rarely been associated with Arthus phenomenon, an immune-complex reaction. In the US, since 2013, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines (Tdap) have been recommended for administration during each pr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563237/ https://www.ncbi.nlm.nih.gov/pubmed/32674495 http://dx.doi.org/10.3390/vaccines8030385 |
_version_ | 1783595445422915584 |
---|---|
author | Pool, Vitali Mege, Larissa Abou-Ali, Adel |
author_facet | Pool, Vitali Mege, Larissa Abou-Ali, Adel |
author_sort | Pool, Vitali |
collection | PubMed |
description | Repeat administration of tetanus toxoid-containing vaccines has rarely been associated with Arthus phenomenon, an immune-complex reaction. In the US, since 2013, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines (Tdap) have been recommended for administration during each pregnancy. Separately, in 2019, one Tdap was approved for repeat administration in adults in the US. We aimed to describe trends in spontaneously reported Arthus reactions following Tdap in the US and to assess the risk of this phenomenon in persons receiving Tdap repeatedly. We reviewed Arthus reports in the Vaccine Adverse Events Reporting System (VAERS), 1990–2018. Reporting rates were estimated using Tdap doses distributed data. A systematic literature review was conducted in MEDLINE for any Arthus cases reported in Tdap clinical trials and observational studies published between 2000 and 2019. We found 192 Arthus reports in VAERS after any vaccine, of which 36 occurred after Tdap and none were reported during pregnancy. The Arthus reporting rate was estimated at 0.1 per million doses distributed. We identified eight published studies of Tdap administration within five years after a previous dose of tetanus toxoid-containing vaccine; no Arthus cases were reported. We conclude that Arthus reaction following Tdap is extremely rare. Increasing frequency of repeat Tdap administration in adults in the US did not result in a detectable increase in reporting rates of this phenomenon, confirming the favorable safety profile of Tdap. |
format | Online Article Text |
id | pubmed-7563237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75632372020-10-27 Arthus Reaction as an Adverse Event Following Tdap Vaccination Pool, Vitali Mege, Larissa Abou-Ali, Adel Vaccines (Basel) Review Repeat administration of tetanus toxoid-containing vaccines has rarely been associated with Arthus phenomenon, an immune-complex reaction. In the US, since 2013, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines (Tdap) have been recommended for administration during each pregnancy. Separately, in 2019, one Tdap was approved for repeat administration in adults in the US. We aimed to describe trends in spontaneously reported Arthus reactions following Tdap in the US and to assess the risk of this phenomenon in persons receiving Tdap repeatedly. We reviewed Arthus reports in the Vaccine Adverse Events Reporting System (VAERS), 1990–2018. Reporting rates were estimated using Tdap doses distributed data. A systematic literature review was conducted in MEDLINE for any Arthus cases reported in Tdap clinical trials and observational studies published between 2000 and 2019. We found 192 Arthus reports in VAERS after any vaccine, of which 36 occurred after Tdap and none were reported during pregnancy. The Arthus reporting rate was estimated at 0.1 per million doses distributed. We identified eight published studies of Tdap administration within five years after a previous dose of tetanus toxoid-containing vaccine; no Arthus cases were reported. We conclude that Arthus reaction following Tdap is extremely rare. Increasing frequency of repeat Tdap administration in adults in the US did not result in a detectable increase in reporting rates of this phenomenon, confirming the favorable safety profile of Tdap. MDPI 2020-07-14 /pmc/articles/PMC7563237/ /pubmed/32674495 http://dx.doi.org/10.3390/vaccines8030385 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pool, Vitali Mege, Larissa Abou-Ali, Adel Arthus Reaction as an Adverse Event Following Tdap Vaccination |
title | Arthus Reaction as an Adverse Event Following Tdap Vaccination |
title_full | Arthus Reaction as an Adverse Event Following Tdap Vaccination |
title_fullStr | Arthus Reaction as an Adverse Event Following Tdap Vaccination |
title_full_unstemmed | Arthus Reaction as an Adverse Event Following Tdap Vaccination |
title_short | Arthus Reaction as an Adverse Event Following Tdap Vaccination |
title_sort | arthus reaction as an adverse event following tdap vaccination |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563237/ https://www.ncbi.nlm.nih.gov/pubmed/32674495 http://dx.doi.org/10.3390/vaccines8030385 |
work_keys_str_mv | AT poolvitali arthusreactionasanadverseeventfollowingtdapvaccination AT megelarissa arthusreactionasanadverseeventfollowingtdapvaccination AT aboualiadel arthusreactionasanadverseeventfollowingtdapvaccination |